Hiddo J.L. Heerspink, Meg Jardine, Donald E. Kohan, Richard A. Lafayette, Adeera Levin, Adrian Liew, Hong Zhang, Amit Lodha, Todd Gray, Yi Wang, Ronny Renfurm, and Jonathan Barrattthe ALIGN Study Investigators*From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.), the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.), the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.), Stanford University, Stanford, CA (R.A.L.), the University of British Columbia, Vancouver, Canada (A. Levin), Mount Elizabeth Novena Hospital, Singapore (A. Liew), Peking University First Hospital, Beijing (H.Z.), Chinook Therapeutics, Seattle (T.G.), Novartis, East Hanover, NJ (A. Lodha, Y.W.), Novartis, Basel, Switzerland (R.R.), and the University of Leicester, Leicester, United Kingdom (J.B.).
{"title":"阿曲生坦在 IgA 肾病患者中的应用","authors":"Hiddo J.L. Heerspink, Meg Jardine, Donald E. Kohan, Richard A. Lafayette, Adeera Levin, Adrian Liew, Hong Zhang, Amit Lodha, Todd Gray, Yi Wang, Ronny Renfurm, and Jonathan Barrattthe ALIGN Study Investigators*From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.), the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.), the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.), Stanford University, Stanford, CA (R.A.L.), the University of British Columbia, Vancouver, Canada (A. Levin), Mount Elizabeth Novena Hospital, Singapore (A. Liew), Peking University First Hospital, Beijing (H.Z.), Chinook Therapeutics, Seattle (T.G.), Novartis, East Hanover, NJ (A. Lodha, Y.W.), Novartis, Basel, Switzerland (R.R.), and the University of Leicester, Leicester, United Kingdom (J.B.).","doi":"10.1056/nejmoa2409415","DOIUrl":null,"url":null,"abstract":"Patients with IgA nephropathy and severe proteinuria have a high lifetime risk of kidney failure. The efficacy and safety of the selective endothelin type A receptor antagonist atrasentan in reduci...","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Atrasentan in Patients with IgA Nephropathy\",\"authors\":\"Hiddo J.L. Heerspink, Meg Jardine, Donald E. Kohan, Richard A. Lafayette, Adeera Levin, Adrian Liew, Hong Zhang, Amit Lodha, Todd Gray, Yi Wang, Ronny Renfurm, and Jonathan Barrattthe ALIGN Study Investigators*From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.), the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.), the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.), Stanford University, Stanford, CA (R.A.L.), the University of British Columbia, Vancouver, Canada (A. Levin), Mount Elizabeth Novena Hospital, Singapore (A. Liew), Peking University First Hospital, Beijing (H.Z.), Chinook Therapeutics, Seattle (T.G.), Novartis, East Hanover, NJ (A. Lodha, Y.W.), Novartis, Basel, Switzerland (R.R.), and the University of Leicester, Leicester, United Kingdom (J.B.).\",\"doi\":\"10.1056/nejmoa2409415\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Patients with IgA nephropathy and severe proteinuria have a high lifetime risk of kidney failure. The efficacy and safety of the selective endothelin type A receptor antagonist atrasentan in reduci...\",\"PeriodicalId\":54725,\"journal\":{\"name\":\"New England Journal of Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":96.2000,\"publicationDate\":\"2024-10-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"New England Journal of Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1056/nejmoa2409415\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"New England Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1056/nejmoa2409415","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
患有IgA肾病和严重蛋白尿的患者终生面临肾衰竭的高风险。选择性内皮素 A 型受体拮抗剂阿曲生坦(astrasentan)在降低 IgA 肾病患者蛋白尿方面的疗效和安全性,以及对肾衰竭患者的治疗效果都具有重要意义。
Patients with IgA nephropathy and severe proteinuria have a high lifetime risk of kidney failure. The efficacy and safety of the selective endothelin type A receptor antagonist atrasentan in reduci...
期刊介绍:
The New England Journal of Medicine (NEJM) stands as the foremost medical journal and website worldwide. With an impressive history spanning over two centuries, NEJM boasts a consistent publication of superb, peer-reviewed research and engaging clinical content. Our primary objective revolves around delivering high-caliber information and findings at the juncture of biomedical science and clinical practice. We strive to present this knowledge in formats that are not only comprehensible but also hold practical value, effectively influencing healthcare practices and ultimately enhancing patient outcomes.